James J. Peters Veterans Affairs Medical Center
62
9
11
38
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.1%
5 terminated/withdrawn out of 62 trials
88.4%
+1.9% vs industry average
18%
11 trials in Phase 3/4
42%
16 of 38 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (62)
Psilocybin to Treat Depression in Spinal Cord Injury
Role: lead
PTSD Prevention Using Oral Hydrocortisone
Role: collaborator
Self-balancing Personal Exoskeleton for SCI
Role: collaborator
Expanding Veteran Sponsorship Initiative+ to Support High-Risk Transitioning Servicemembers and Veterans: A Precision Medicine Approach
Role: collaborator
Cough Capture as a Portal Into the Lung
Role: collaborator
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
Role: collaborator
Pharmacokinetics of Neostigmine and Glycopyrrolate
Role: lead
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
Role: lead
Transdermal Administration by a Novel Wireless Iontophoresis Device
Role: lead
Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI
Role: lead
Seated Balance Using the Indego™
Role: lead
Home/Work, Community Mobility Skills in the ReWalk Exoskeleton in Persons With SCI
Role: lead
TSCS for Acute SCI
Role: collaborator
Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia
Role: lead
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
Role: lead
Treatment of Post-SCI Hypotension
Role: lead
Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury
Role: lead
RAAS and Arterial Stiffness in SCI
Role: lead
Autonomic Effects of Spinal Cord Stimulation in Spinal Cord Injury
Role: lead
Treatment of Orthostatic Hypotension in SCI
Role: lead